 |
Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
Apr 17, 2009
|
13.4 KB |
|
| |
SUNNYVALE, Calif., April 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has entered into a global strategic alliance with Servier, the leading French independent pharmaceutical company. The alliance will focus on the research, development, and commercialization of Pharmacyclics'...
|
|
Pharmacyclics Updates Positive Clinical Responses in its PCI-24781 Clinical Program Targeting HDAC
Apr 16, 2009
|
14.6 KB |
|
| |
SUNNYVALE, Calif., Apr 16, 2009 (BUSINESS WIRE) -- Pharmacyclics, Inc. (NASDAQ:PCYC) today announced an update to its
clinical programs targeting histone deacetylase (HDAC) with its drug
candidate PCI-24781 that is currently in multiple clinical trials for
treating various solid and hematologic tumors. In addition, the Compa...
|
|
Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma
Apr 13, 2009
|
14.0 KB |
|
| |
SUNNYVALE, Calif., April 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc.
(Nasdaq: PCYC) today announced that it has begun treating patients in a Phase
1 dose-escalation study to evaluate the safety and tolerability of PCI-32765,
an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk,
as a pot...
|
|
Pharmacyclics Announces Dr. Ahmed Hamdy as New Chief Medical Officer
Mar 16, 2009
|
11.0 KB |
|
| |
SUNNYVALE, Calif., March 16, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today the appointment of Dr. Ahmed Hamdy as its new Chief Medical Officer. Dr. Hamdy most recently served as Therapeutic Area Head at Elan Pharmaceuticals responsible for gastroenterology and autoimmune clinical developm...
|
|
Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
Feb 20, 2009
|
9.5 KB |
|
| |
SUNNYVALE, Calif., Feb 20, 2009 /PRNewswire via COMTEX News Network/ -- SUNNYVALE, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Pharmacyclics (Nasdaq: PCYC) announced today the close of a financing in connection with an investment by the principals of Pacific Biopharma Group, Ltd. (PBG), located in San Bruno California and Taizhou, Jiangsu Province, P...
|
|
Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
Feb 13, 2009
|
14.4 KB |
|
| |
SUNNYVALE, Calif., Feb 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc.
(Nasdaq: PCYC) today reported financial results for its second fiscal quarter
ended December 31, 2008. The net loss for the second quarter of fiscal 2009
was $4.8 million, or $0.19 per share, compared to a net loss of $5.9 million,
or $0.23 per...
|
|
Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
Feb 12, 2009
|
13.5 KB |
|
| |
SUNNYVALE, Calif., Feb 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc.
(Nasdaq: PCYC), a developmental stage biopharmaceutical company with four drug
candidates in clinical testing and several late stage preclinical programs,
announced today the appointment of a new management team and a new board
member.
Robert ...
|
|
Pharmacyclics Secures $5.0 Million in Debt Financing
Jan 6, 2009
|
10.5 KB |
|
| |
SUNNYVALE, Calif., Jan 06, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc.
(Nasdaq: PCYC) today announced that in preparation of further equity
offerings, Robert W. Duggan & Associates ("RWD") made an unsecured loan to
Pharmacyclics, Inc. on December 30, 2008, in the amount of $5,000,000. As of
December 31, 2008, the...
|
|
Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
Nov 25, 2008
|
12.4 KB |
|
| |
SUNNYVALE, Calif., Nov 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc.
(Nasdaq: PCYC) today announced that the company has completed a Phase 1
clinical trial with PCI-27483, the company's novel, first-in-class
small-molecule Factor VIIa inhibitor. The trial was conducted in sixteen (16)
healthy volunteers to evalu...
|
|
Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
Oct 30, 2008
|
12.0 KB |
|
| |
SUNNYVALE, Calif., Oct 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its first fiscal quarter ended September 30, 2008. The net loss for the first quarter of fiscal 2009, was $6.5 million, or $0.25 per share, compared to a net loss of $6.8 million, or $0.26 per sha...
|
|
Pharmacyclics Responds to Nasdaq Letter
Sep 30, 2008
|
8.9 KB |
|
| |
SUNNYVALE, Calif., Sept 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has provided Nasdaq with a plan and timetable as described below, which it believes will achieve compliance with Nasdaq Marketplace Rule 4350(d)(2), which requires Nasdaq-listed companies to have an Audit Com...
|
|
Pharmacyclics, Inc. Announces Board and Management Transitions
Sep 11, 2008
|
15.4 KB |
|
| |
SUNNYVALE, Calif., Sept 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (the "Company" or "Pharmacyclics") announced today that Christine A. White, M.D., Richard M. Levy Ph.D., Mr. Miles R. Gilburne and Richard A. Miller, M.D. have resigned as members of the Board of Directors of the Company, effective immediately. Th...
|
|
Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
Aug 14, 2008
|
15.1 KB |
|
| |
SUNNYVALE, Calif., Aug 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its fourth quarter and fiscal year ended June 30, 2008. The net loss for the fourth quarter of fiscal 2008 was $4.6 million, or $0.18 per share, compared to a net loss of $7.0 million, or $0.27 pe...
|
|
Pharmacyclics Announces Conference Call to Discuss Fourth Quarter and Fiscal 2008 Year-End Results
Aug 7, 2008
|
8.4 KB |
|
| |
SUNNYVALE, Calif., Aug 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it will hold a conference call to discuss its fourth quarter and fiscal 2008 year-end financial results and achievements, and 2009 guidance on Thursday, August 14, 2008, at 4:30 p.m. EDT (1:30 p.m. PDT).
To p...
|
|
Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
Jun 9, 2008
|
11.5 KB |
|
| |
SUNNYVALE, Calif., June 9, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced results from a preclinical study evaluating PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, in collagen induced arthritis, an established animal model for rheumatoid arthritis ...
|
|
Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma
Jun 5, 2008
|
12.4 KB |
|
| |
SUNNYVALE, Calif., June 5, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced final data from a Phase 1/2 study showing a 46 percent complete response rate in patients with multiply recurrent non-Hodgkin's lymphoma (NHL) who were treated with motexafin gadolinium (MGd, Xcytrin(R)) in combinatio...
|
|
Pharmacyclics Announces It Received Nasdaq Notice of Compliance
May 30, 2008
|
8.0 KB |
|
| |
SUNNYVALE, Calif., May 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has received notice from The Nasdaq Stock Market that the company has regained compliance with Marketplace Rule 4450(a)(5) (the "Rule") relating to the maintenance of a minimum $1.00 bid price of the Company's...
|
|
Pharmacyclics Files Schedule 14D-9 Statement with Securities and Exchange Commission
May 14, 2008
|
9.6 KB |
|
| |
SUNNYVALE, Calif., May 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that it has filed a Schedule 14D-9 Solicitation/Recommendation Statement with the Securities and Exchange Commission (the "Commission"), as required by the Commission's rules, in response to an unsolicited tender offe...
|
|
Pharmacyclics Reports Third Quarter 2008 Financial Results
Apr 24, 2008
|
14.6 KB |
|
| |
SUNNYVALE, Calif., April 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its third fiscal quarter ended March 31, 2008. The net loss for the third quarter of fiscal 2008 was $7.0 million, or $0.27 per share, compared to a net loss of $6.8 million, or $0.26 per share,...
|
|
Pharmacyclics Announces It Received Nasdaq Notification
Apr 21, 2008
|
8.1 KB |
|
| |
SUNNYVALE, Calif., April 21, 2008 /PRNewswire via COMTEX News Network/ -- SUNNYVALE, Calif., April 21 /PRNewswire-FirstCall/-- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it received a Nasdaq staff deficiency letter on April 17, 2008 indicating that, for the last 30 consecutive days, the bid price for Pharmacyclics' common stock has clo...
|
|
|
